Digital Cognitive Scores May Streamline Alzheimer Disease Biomarker Testing

Linus Health will present new data on digital risk scores for dementia and patient-centered outcome measures at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026), taking place March 17-21, 2026, in Copenhagen, Denmark, and online. The company will showcase 3 poster presentations focused on multimodal digital assessments designed to support identification of candidates for emerging Alzheimer disease therapies and to incorporate patient priorities into research endpoints.

Ali Jannati, MD, PhD, Director of Cognitive Science at Linus Health, will present two posters. Poster #1367 evaluates the use of the Digital Clock and Recall (DCR™), combining the DCR Cognition Score and Amyloid Positivity Risk. According to the company, the multimodal, machine-learning models demonstrated strong performance in identifying individuals in earlier symptomatic stages, including mild cognitive impairment or mild dementia likely due to Alzheimer disease, who may be appropriate candidates for disease-modifying therapies.

Poster #1925 examines prediction of plasma p-tau217 status and Alzheimer disease risk using the remote-ready Digital Assessment of Cognition (DAC). The company reports that the approach showed high classification accuracy and negative predictive value as a front-end screener, potentially helping to prioritize confirmatory testing and reduce unnecessary biomarker testing for low-likelihood candidates.

“These findings underscore the growing role of digital, biologically anchored cognitive assessments in identifying and stratifying participants for Alzheimer’s research,” Jannati said in a press release. “By pairing high-resolution cognitive performance signals with biomarker risk estimation – such as amyloid-PET and plasma p-tau217 – we can more efficiently prioritize who should move to confirmatory testing, reduce unnecessary procedures, and accelerate recruitment while maintaining scientific rigor.”

A third poster, presented by Stina Saunders, PhD, Personalized Medicine Lead at Linus Health, will report on feasibility and acceptability of the Electronic Person Specific Outcome Measures (ePSOM) tool in a Japanese memory clinic population (Poster #2179). The study evaluates implementation of culturally responsive, person-specific outcome measures in patients with early symptomatic Alzheimer disease.

“As new treatments for Alzheimer’s disease emerge, it is essential that study endpoints incorporate the participant perspective of what matters most across cultures,” Saunders noted in the press release. “Our results support the feasibility of implementing individualized outcome measures in diverse clinical environments across multiple countries.”

References:

1. Linus Health to Present New Findings on Digital Risk Scores for Dementia and Patient-Centered Endpoints at Leading Global Alzheimer’s and Parkinson’s Conference. News release. Linus Health. March 3, 2026. Accessed March 3, 2026. https://linushealth.com/press-releases/linus-presents-research-at-global-alzheimers-and-parkinsons-conference